Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial compares toripalimab plus axitinib against sunitinib monotherapy in unresectable or metastatic renal cell carcinoma; the study status is Comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)
• Sutent (sunitinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 | Phase 3 | Status: COMPLETED